Tumor-Immune Signatures Associated with Response or Resistance to Tislelizumab (ANTI-PD1) in Esophageal Squamous Cell Carcinoma (ESCC)
Xu, J., et al. Tumor-Immune Signatures Associated with Response or Resistance to Tislelizumab (ANTI-PD1) in Esophageal Squamous Cell Carcinoma (ESCC) Journal for Immunotherapy of Cancer 2020(8)S3:A1-A959